🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A hot topic of conversation and another 🚨 PGY2 CE Spotlight 🚨 Duke Cardiology PGY2 Resident Kyle Fischer, PharmD, BCCP, MBA weighs in on the importance of rapid initiation of GDMT in the face of persisting clinical inertia in HFrEF patients! Quicker intentional initiation = better outcomes!!

I am picking up a lot of new followers - Initially learning lipids is like learning a new language. For those starting the journey here is a link to mastering lipid terminology peterattiamd.com/glossary-lipid…

Asthma overview Kyle Fischer, PharmD, BCCP, MBA #MedEd #Medtwitter

Great time American College of Cardiology talking about my residency research. 🫀 #ACC23 Cody Carson Monique Conway Godfrey, PharmD, BCCP Kristen Campbell Jason N. Katz

Great work by the pharmacy residency superstar Kyle Fischer, PharmD, BCCP, MBA!!! ⭐️⭐️⭐️ Duke Heart

Commenting on COORDINATE-Diabetes, Dr. Kristen Campbell says the “multifaceted design is notably simple and that’s particular strength to this trial,” adding “These results can be extrapolated to different disease states.” #ACC23/#WCCardio

Best RPD Kristen Campbell 🥲 - a tremendous privilege to get to learn from her!!

🆕 ACC Expert Consensus Decision Pathway on the Management of #HFpEF addresses diagnostic challenges tied to EF threshold, correct terminology, gender/sex differences, & the lack of a single test that definitively establishes Dx. bit.ly/41phjhE #JACC #CardioTwitter

“Dr. Lipids” otherwise know as our PGY2 Cardiology 🫀 resident Kyle Fischer, PharmD, BCCP, MBA had the opportunity to teach at the Duke University School of Medicine today - congratulations on a great lecture, Kyle! #statinisland

Should ApoB be applied widely in clinical care? Multiple expert groups have confirmed its accuracy, precision, and selectivity surpass that of LDL-C and non-HDL-C. The future looks bright w/ mass spec methods enhancing standardization. #AHAJournals #Review ahajrnls.org/3DSrYqS

Check out this new Journal of Cardiothoracic and Vascular Anesthesia article describing our use of #cangrelor in MCS. A brief summary 🧵 and link to article below! Saint Luke's Mid America Heart Institute UMKC School of Medicine Saint Luke's Pharmacy Residency Program

Management of Status Epilepticus. Any comments? Credits: Kyle Fischer, PharmD, BCCP, MBA #MedTwitter

Iron Deficiency in Heart Failure Kyle Fischer, PharmD, BCCP, MBA #TipsForNewDocs #MedEd #MedTwitter #medicine #medical #medicare #health #healthcare #FOAMed #ClinicalPearl #clinicaltips #MedStudents #HeartFailure #MedX

ApoB is a great biomarker that aggregates so much information, which is not the case with others. ApoB is a measurement of the total number of atherogenic particles. Each CM, VLDL, IDL, LDL, & Lp(a) has one ApoB per particle. Measuring ApoB allows optimal ASCVD risk assessment!

Despite overwhelming evidence, <50% of statin-eligible patients receive treatment. This work evaluates the efficacy of a consumer-facing web app for non-prescription statin selection. bit.ly/3Kbi8mX #JACC #CardioTwitter #Cardiology

👉ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines? ☝️ In conclusion, the era of focusing solely on LDL-C for assessing cholesterol-driven risk is coming to an end. ☝️These findings advocate for the integration of apoB as a central

1/ There is controversy on the selection of antiplatelet drugs for people with CVD. This supports testing for CYP2C219 LOF gene variants to guide clinical antiplatelet drug treatment. Naveen Pereira SharonCresciMD Wayne Batchelor, MD Quinn Capers, IV Dan M Roden MD Konstantinos Stellos @sony_tuteja

Mechanistic Differences between Torsemide and Furosemide Prospective data debunks classic teachings 🔵No meaningful PK/PD advantages for T 🔵Kidney bioavailability less w T 🔵Ratio T:F was 4:1 (not 2:1!) 🔵T w ⬆️neurohormonal activ & kidney dysfunction journals.lww.com/jasn/abstract/…

Updated summary for MRAs in heart failure with ejection fraction >40% including TOPCAT, FINEARTS-HF, & the Lancet IPD meta-analysis: nerdcat.org/studysummaries… IMO, clear class effect of MRAs in these patients. Remains important to walk the efficacy/safety trade-off tightrope

Check out this incredible #TeachingTuesday post on LV thrombus by Zaynab Omisade and her mentor Kyle Fischer, PharmD, BCCP, MBA! Do you initiate loading doses for DOACs in your practice?